58 research outputs found
FIG. 4. — Mandibules des nauplies d in Le cycle biologique d'Acanthocyclops robustus (G. O. Sars, 1863) (Crustacea, Copepoda, Cyclopidae) de Tunisie
No full textFIG. 4. — Mandibules des nauplies d'Acanthocyclops robustus (G. O. Sars, 1863); A, nauplie 1; B, nauplie 2; C, nauplie 3; D, nauplie 4; E, nauplie 5; F, nauplie 6. Abréviations: Bsp, basoendopodite; Cx, coxopodite; Enp, endopodite; Exp, exopodite. Les flèches indiquent l'apparition de nouvelles soies à chaque stade. Échelle: 50 µm.Published as part of Turki, Souâd, Defaye, Danielle, Rezig, Mohamed & Abed, Amor El, 2002, Le cycle biologique d'Acanthocyclops robustus (G. O. Sars, 1863) (Crustacea, Copepoda, Cyclopidae) de Tunisie, pp. 735-770 in Zoosystema 24 (4) on page 742, DOI: 10.5281/zenodo.468946
PHYSICOCHEMICAL CHARACTERISTICS AND ANTIOXIDANT ACTIVITIES OF ZIZYPHUS LOTUS L. SEED OIL
No full textThis study was designed to examine both the chemical composition as well as the antioxidant activities of the seed oil extracted from Zizyphus lotus L. The results showed that the neutral lipids were mainly composed of triacylglycerols (92.75% of total lipids). Phosphatidylcholine and digalactosyldiacylglycerol were the main phospholipid and glycolipid subclasses, respectively. Oleic, linoleic and palmitic acids were the major fatty acids in the lipids of Z. lotus seeds. In addition, b-tocopherol was the predominant tocol at 122.13 mg/100 g seed oil, which was equivalent to 60.41% of the total tocols followed by d-tocopherol (13.30%) and d-tocotrienol (8.95%). The total phenol and flavonoid contents were 18.45 mg/100 g and 2.31 QE/g oil, respectively, with ferulic acid as the main phenolic acid (1.36 mg/100 g oil). Overall, the strong antioxidant activities suggest that it could be advantageously used as a functional or nutraceutical food in order to prevent or moderate oxidative stress-related diseases
Exploring potential new galactomannan source of Retama reatam seeds for food, cosmetic and pharmaceuticals: Characterization and physical, emulsifying and antidiabetic properties
No full textIn this study, physicochemical, interfacial and emulsifying properties of Retama reatam and guar galactomannans were comparatively investigated. The results showed that Retama reatam galactomannan is mainly composed of total carbohydrates (95.52%) and lower protein contents (0.87%). The sugars identified were mannose (Man) and galactose (Gal), with a Man:Gal ratio of 1.85 compared to guar gum (1.83). The results of thermal properties indicated were transition temperature (T g ) and melting temperature (T m ) very similar to those of the guar gum. Moreover, results also revealed that there is no significant difference in terms of equilibrium interfacial tension of Retama reatam gum at 10 and 20 °C. Moreover, preliminary tests show that stable oil-in-water nanoemulsions may be formulated using Retama reatam gum. Therefore, measurement of mean oil droplet diameter d after heating at 80 °C, shows that stable nanoemulsions may be formulated using Retama reatam galactomannan. Further in vivo experiments confirmed that Retama reatam gum can reduce the glycemic index of starchy foods and inhibit the surge of postprandial blood glucose level
Systemic administration of glucocorticoids, cardiovascular complications and mortality in patients hospitalised with COVID-19, SARS, MERS or influenza: A systematic review and meta-analysis of randomised trials
No full textBackground: Administration of glucocorticoids might reduce mortality in patients with severe COVID-19 but have adverse cardiometabolic effects. Objectives: to investigate the effect of systemic administration of glucocorticoids on cardiovascular complications and all-cause mortality in patients hospitalised with respiratory viral infections, including COVID-19, SARS, MERS and influenza. Methods: We identified randomised trials published prior to July 28th, 2021. The Mantel-Haenszel random effects method and the Hartung and Knapp adjustment were used to obtain pooled estimates of treatment effect with 95% confidence intervals. Results: No randomised trials of glucocorticoids for SARS, MERS or influenza reported relevant outcomes. We included eleven COVID-19 randomised trials (8109 patients). Overall, compared to placebo or standard care, glucocorticoids were not associated with a reduction of in-hospital mortality (p = 0.09). In a pre-specified sub-analysis, in-hospital mortality was reduced by 19% when follow-up was restricted to 14 days from randomisation (5/11 trials, 1329 patients, p = 0.02). With longer follow-up (9/11 trials, 7874 patients), administration of glucocorticoids was associated with a trend to benefit for those requiring mechanical ventilation (RR 0.86; 95% CI 0.57–1.27) but possible harm for those not receiving oxygen at randomisation (RR 1.27; 95% CI 1.00 – 1.61), an effect that was significantly different amongst subgroups (p = 0.0359). Glucocorticoids reduced the risk of worsening renal function by 37% (4/11 trials); reported rate of other cardiovascular complications was low. Conclusions: Administration of systemic glucocorticoids to patients hospitalised with COVID-19 does not lower mortality overall but may reduce it in those requiring respiratory support and increase it in those who do not
Facies analysis and depositional environment prediction using advanced borehole image analysis
No full textCoronary revascularization for heart failure with coronary artery disease: A systematic review and meta-analysis of randomized trials
No full textAims: Coronary artery disease (CAD) is a common cause of heart failure (HF). Whether coronary revascularization improves outcomes in patients with HF receiving guideline-recommended pharmacological therapy (GRPT) remains uncertain; therefore, we conducted a systematic review and meta-analysis of relevant randomized controlled trials (RCTs). Methods and results: We searched in public databases for RCTs published between 1 January 2001 and 22 November 2022, investigating the effects of coronary revascularization on morbidity and mortality in patients with chronic HF due to CAD. All-cause mortality was the primary outcome. We included five RCTs that enrolled, altogether, 2842 patients (most aged <65 years; 85% men; 67% with left ventricular ejection fraction ≤35%). Overall, compared to medical therapy alone, coronary revascularization was associated with a lower risk of all-cause mortality (hazard ratio [HR] 0.88, 95% confidence interval [CI] 0.79–0.99; p = 0.0278) and cardiovascular mortality (HR 0.80, 95% CI 0.70–0.93; p = 0.0024) but not the composite of hospitalization for HF or all-cause mortality (HR 0.87, 95% CI 0.74–1.01; p = 0.0728). There were insufficient data to show whether the effects of coronary artery bypass graft surgery or percutaneous coronary intervention were similar or differed. Conclusions: For patients with chronic HF and CAD enrolled in RCTs, the effect of coronary revascularization on all-cause mortality was statistically significant but neither substantial (HR 0.88) nor robust (upper 95% CI close to 1.0). RCTs were not blinded, which may bias reporting of the cause-specific reasons for hospitalization and mortality. Further trials are required to determine which patients with HF and CAD obtain a substantial benefit from coronary revascularization by either coronary artery bypass graft surgery or percutaneous coronary intervention
Contract net protocol for cooperative optimisation and dynamic scheduling of steel production
No full textPhylogenetic Analysis of Echovirus 11 in the 3′ End of the VP1
No full textInternational audienceObjective: Echovirus 11 is one of the most frequently isolated enterovirus serotypes, causing a wide range of clinical diseases. We studied the genetic diversity in the 3' end of the VP1 gene of strains from different geographical origin in the world. Methods: The sequences in the 3' end of the VP1 of 11 Tunisian isolates were determined and aligned with the published sequences to establish a phylogenetic profile. Results: The grouping of the sequences was similar to what was previously reported by analyzing the whole VP1 gene with 4 genogroups, designated A-D, and 5 lineages in genogroup D. All Tunisian strains belonged to genogroup D, together with other sequences mainly from the USA and Europe. Contrary to the sequences from the USA isolated during the last 3 decades, which mostly belonged to the D4 lineage, those from Tunisia belonged to different lineages within genogroup D according to their isolation date: isolates from the early 1990s belonged to D3, those of the mid 1990s to D4 and the most recent ones to D5. Conclusion: Our findings further widen the interest of partial sequencing in the VP1 to study the molecular epidemiology of echovirus 11 and indicate that the genetic evolution of circulating strains may differ from one country to another according to the region's epidemiological specificities. Copyright (c) 2007 S. Karger AG, Basel
- …
